Methylphenidate in ADHD With Trichotillomania

Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00552266

Enrollment

Registered

2007-11-01

Start date

2007-10-31

Completion date

2009-10-31

Last updated

2007-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD, Trichotillomania

Keywords

Methylphenidate, Trichotillomania, Attention deficit

Brief summary

This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and trichotillomania. Trichotillomania is an impulse control disorder. There is growing evidences of the involvement of dopaminergic neurotransmission in the pathophysiology of trichotillomania. Reported increase in the prevalence of ADHD among patients with impulse control disorders, such as pathological gambling as well as trichotillomania, may result from the overlapping pathophisiological background. It is hypothesized that in cases of ADHD comorbid with trichotillomania methtylphenidate treatment will exhibit beneficial effects in both the ADHD and the hair pulling.

Detailed description

Thirty children and adolescents aged 6-18 years, diagnosed with ADHD and trichotillomania, will receive MPH monotherapy treatment for a period of 12 weeks, targeting both ADHD and trichotillomania symptoms as rated by the ADHD- rating scale (ADHD-RS) and by the Massachusetts General Hospital Hair Pulling Scale and Clinical Global Impression-Severity (CGI) scale. The rating scales will be assessed at baseline and at the endpoint (after 12 weeks).The side effects will be monitored via weekly spontaneous self reports by each participant. All results will be expressed as mean ±SD. Student's paired t-test and ANOVA test will be used as appropriate.

Interventions

DRUGMethylphenidate

tablets 10-60 mg/day administered once or twice daily 6 weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to 18 Years

Healthy volunteers

Inclusion criteria

* DSM-IV Diagnosis of trichotillomania * DSM-IV diagnosis of ADHD * Has not taken stimulants or alpha-adrenergic medications for more than 2 weeks prior to entering the study.

Exclusion criteria

* History of moderate or severe adverse event, related to MPH * History of any psychotic disorder * Current drug abuse, acute psychotic or affective disorder

Design outcomes

Primary

Measure	Time frame
Clinicial administered Massachusetts General Hospital Hair Pulling Scale for trichotillomania	First 6 weeks of treatment

Secondary

Measure	Time frame
Clinicial administered ADHD Rating Scale Clinical Global Impressions (CGI) scale for ADHD severity Weekly spontaneous self report of side effects	Within the first 6 weeks of treatment

Countries

Israel

Contacts

Primary ContactPavel Golubchik, M.D.

pgolubchik@clalit.org.il+972-3-925-8270

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026